AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37556913
Drug: BI 894999
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 894999 (Schedule A: 0.2, 0.5, 1.0, 1.5, 2.0, and 5.0 mg, Days 1-21/21-d cycle)
Trial: 37556913
Drug: BI 894999
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 894999 (Schedule B: 1.5, 2.0, and 2.5 mg, Days 1-15/21-d cycle)
Trial: 37556913
Drug: BI 894999
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 894999 (Schedule C: loading dose 5.0, 6.0, or 7.0 mg on Day 1 followed by maintenance dose 2.5, 3.0, or 3.5 mg, Days 2-7 and 15-21/28-d cycle)
Trial: 37558400
Drug: Disease-modulating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modulating therapy (DMT)
Trial: 37559023
Drug: Standard adequate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adequate haemodialysis with a dialysate potassium concentration of 2.0 mmol/L
Trial: 37559050
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg per day for 21 days every 28 days
Trial: 37559530
Drug: Caffeine therapy
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine therapy (n = 12)
Trial: 37559530
Drug: No caffeine
RxNorm normalized name: caffeine Oral Tablet [No Doz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No caffeine therapy (n = 16)
Trial: 37559753
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg lufotrelvir (SAD)
Trial: 37559753
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg lufotrelvir (SAD)
Trial: 37559753
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg lufotrelvir (MAD)
Trial: 37559753
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg lufotrelvir (MAD)
Trial: 37560813
Drug: Immunochemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy with dose reduction in patients ≤55 years old after achieving complete metabolic response (CMR)
Trial: 37560813
Drug: Immunochemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy with standard dose (BURKIMAB08 trial)
Trial: 37561249
Drug: Orbital radiotherapy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital radiotherapy (OR) with a total dose of 20 Gy, divided into 10 sessions of 2 Gy each, with concomitant oral intake of low-dose glucocorticoids.
Trial: 37561451
Drug: Pertuzumab plus
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab plus trastuzumab without chemotherapy (group A)
Trial: 37561451
Drug: Pertuzumab plus
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab plus trastuzumab with chemotherapy (group B)
Trial: 37562004
Drug: OAsIs combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAsIs combination therapy (targeted therapies against CD20, BCL2, and Bruton tyrosine kinase)
Trial: 37562063
Drug: Imipenem/cilastatin/relebactam (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin/relebactam (maximum dose of 15 mg/kg imipenem and 15 mg/kg cilastatin, 7.5 mg/kg relebactam)
Trial: 37562095
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg BID or 1500 mg BID) combined with platinum-based chemoradiation
Trial: 37562095
Drug: Metformin compliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin compliance ≥70%
Trial: 37562641
Drug: BI 1026706
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1026706 100 mg bid
Trial: 37562934
Drug: Codesigned complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codesigned complex intervention to prevent pressure ulcers, malnutrition, poor oral health and falls
Trial: 37563004
Drug: Eliapixant 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant 125 mg twice daily
Trial: 37563240
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus tremelimumab combined with mFOLFOX6 chemotherapy
Trial: 37563568
Drug: hrBMP4 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hrBMP4 (0.5 to 18 mg)
Trial: 37564370
Drug: Therapeutic SCiP™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic SCiP™ therapy for 8 weeks (G2)
Trial: 37564370
Drug: Therapeutic SCiP™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic SCiP™ therapy for another 8 weeks (G2)
Trial: 37564370
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation followed by therapeutic SCiP™ therapy for 8 weeks (G1)
Trial: 37564370
Drug: Activity-based neurorehabilitation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-based neurorehabilitation therapy (ABNT) 2 days/week for both groups
Trial: 37565393
Drug: Trial-related blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial-related blood sampling (1.6 ± 0.6 mL/kg)
Trial: 37565393
Drug: Clinical blood
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical blood sampling (8.1 ± 5.1 mL/kg)
Trial: 37565541
Drug: Lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 10 mg oral dose
Trial: 37566253
Drug: Community-based multidisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based multidisciplinary group intervention program (10-week duration, including twice-weekly exercise sessions and weekly education sessions)
Trial: 37566578
Drug: OT infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OT infusion at 3.3 mU/min in women with morbid obesity
Trial: 37566578
Drug: OT infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OT infusion in women with non-obesity and obesity
Trial: 37566578
Drug: OT infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OT infusion in women with obesity
Trial: 37566578
Drug: OT infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OT infusion in women with morbid obesity
Trial: 37567205
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir (600 mg) plus rilpivirine (900 mg) dosed intramuscularly every 2 months
Trial: 37567205
Drug: Bictegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) taken daily
Trial: 37567750
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg two times a day
Trial: 37568076
Drug: One-Level ESPB
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-Level ESPB (n=30) with 30 ml 0.25% bupivacaine
Trial: 37568076
Drug: Bi-Level ESPB
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-Level ESPB (n=30) with 15 ml 0.25% bupivacaine at T4 and T6 levels
Trial: 37568158
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (20 g thrice a day for 4 weeks)
Trial: 37568381
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate 2 hours before elective cesarean delivery
Trial: 37568391
Drug: Posterior tibial
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior tibial nerve stimulation (PTNS) with duloxetine (30 mg/day)
Trial: 37568391
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 mg/day) only
Trial: 37568622
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 21 days
Trial: 37570430
Drug: Educational solutions
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational solutions (360 V, VR, web-based information, psychoeducation)
Trial: 37572086
Drug: Ibrutinib maintenance
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib maintenance (560 mg/d)
Trial: 37572581
Drug: Locally produced
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally produced fish-based ready-to-use therapeutic food (L-RUTF)
Trial: 37572581
Drug: Both L-RUTF
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both L-RUTF and S-RUTF
Trial: 37572659
Drug: ChAd63-MVA RH5
RxNorm normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd63-MVA RH5 vaccine
Trial: 37573322
Drug: CR500® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR500® treatment applied topically twice a week for 4 weeks
Trial: 37573322
Drug: CR500® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR500® treatment
Trial: 37573421
Drug: Weekly multi-disciplinary
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly multi-disciplinary team-based case consultation and peer-to-peer sharing of emerging best practices (teleECHO) with monthly interactive webinars and quarterly short courses
Trial: 37573421
Drug: Monthly interactive
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly interactive webinars and quarterly short courses
Trial: 37573936
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) (25.0% of patients, mean duration 26.2 ± 23.2 days)
Trial: 37573936
Drug: Any other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any other anticoagulants (6.2%)
Trial: 37573936
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant (6.7%)
Trial: 37573968
Drug: Physician-guided discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-guided discontinuation
Trial: 37574132
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily (7-d lead-in, 90 mg)
Trial: 37574132
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (exploratory analysis)
Trial: 37574780
Drug: Ad-HSV1-TK/GCV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad-HSV1-TK/GCV and Ad-Flt3L gene therapy
Trial: 37574821
Drug: Tandem infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem infusions of MIITOP
Trial: 37574821
Drug: Tandem infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem infusions of MIITOP followed by busulfan-melphalan
Trial: 37574953
Drug: lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks (with possible reduction to 300 mg every 4 weeks during the second 26-week period if well-controlled)
Trial: 37574953
Drug: lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanadelumab 300 mg every 2 weeks subcutaneously for 52 weeks
Trial: 37575149
Drug: Emollient+ used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient+ used at least once daily
Trial: 37575420
Drug: VR-guided meditation
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR-guided meditation intervention (8 sessions of 15-min each, twice weekly for 4 weeks)
Trial: 37576973
Drug: Extracellular vesicle-enriched
RxNorm normalized name: Bos taurus testicle preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracellular vesicle-enriched preparations from participants with T1D
Trial: 37576973
Drug: Extracellular vesicle-enriched
RxNorm normalized name: Bos taurus testicle preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracellular vesicle-enriched preparations from healthy normal volunteers (Controls)
Trial: 37577112
Drug: Sotrovimab 500
RxNorm normalized name: sotrovimab 500 MG in 8 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrovimab 500 mg IM injection
Trial: 37577112
Drug: Sotrovimab 250
RxNorm normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Sotrovimab 250 mg IM injection
Trial: 37577293
Drug: Ephedrine usage,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine usage, hypothermia, need for additional analgesics, nausea, and vomiting
Trial: 38306745
Drug: Delandistrogene moxeparvovec
RxNorm normalized name: Delandistrogene moxeparvovec
DrugBank: Delandistrogene moxeparvovec (DB16802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delandistrogene moxeparvovec gene therapy
Trial: 37577796
Drug: NCTF®135HA injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCTF®135HA injections plus twice-daily anti-aging moisturizer cream
Trial: 37577796
Drug: Anti-aging moisturizer
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 8 g in 100 mL / OCTINOXATE 7.5 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL CREAM [MURAD - ANTI-AGING MOISTURIZER SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-aging moisturizer cream alone
Trial: 37577798
Drug: Mepolizumab (anti-IL-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (anti-IL-5 therapy)
Trial: 37577801
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (1 Hz rTMS)
Trial: 37577817
Drug: PegIFNα-2b treatment
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PegIFNα-2b treatment for 68 weeks
Trial: 37577817
Drug: PegIFNα-2b-based immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα-2b-based immunotherapy (two cycles with GM-CSF and vaccine treatment)
Trial: 37577967
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow aspirate concentrate treatment
Trial: 37578052
Drug: Wireless motility
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless motility capsule test
Trial: 37578099
Drug: Burosumab treatment
RxNorm normalized name: Burosumab
DrugBank: Burosumab (DB14012)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Burosumab treatment for 48 weeks
Trial: 37578099
Drug: Burosumab treatment
RxNorm normalized name: Burosumab
DrugBank: Burosumab (DB14012)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Burosumab treatment for 144 weeks (exploratory analysis)
Trial: 37578099
Drug: Burosumab treatment
RxNorm normalized name: Burosumab
DrugBank: Burosumab (DB14012)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Burosumab treatment for 144 weeks (SF-36 v2 scores)
Trial: 37578113
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis for a duration of 24 hours
Trial: 37578113
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis for a duration longer than 24 hours
Trial: 37578188
Drug: Glucose-lowering therapies
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-lowering therapies
Trial: 37578437
Drug: Facet Joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facet Joint Injection (FIJ)
Trial: 37578791
Drug: Ginkgo diterpene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo diterpene lactone meglumine (GDLM) administered once daily via intravenous infusion for 14 days.
Trial: 37578791
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once daily via intravenous infusion for 14 days.
Trial: 37579053
Drug: Leflutrozole 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflutrozole 0.1 mg
Trial: 37579053
Drug: Leflutrozole 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflutrozole 0.3 mg
Trial: 37579053
Drug: Leflutrozole 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflutrozole 1.0 mg
Trial: 37579053
Drug: Leflutrozole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflutrozole (all doses)
Trial: 37579053
Drug: Leflutrozole (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflutrozole (0.1 mg, 0.3 mg, 1.0 mg)
Trial: 37579116
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg subcutaneously once-weekly for 6 weeks
Trial: 37579116
Drug: Standard individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard individual drug counseling
Trial: 37579773
Drug: MenABCWY vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenABCWY vaccine (0.5 mL, months 0 and 6)
Trial: 37579773
Drug: MenB-FHbp and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenB-FHbp and MenACWY-CRM (two doses of MenB-FHbp and one dose of MenACWY-CRM)
Trial: 37580498
Drug: MP-AzeFlu nasal
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-AzeFlu nasal spray (one spray per nostril twice daily for 14 days)
Trial: 37580498
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride nasal spray (AZE)
Trial: 37580498
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (FLU)
Trial: 37580498
Drug: MP-AzeFlu nasal
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-AzeFlu nasal spray
Trial: 37580661
Drug: Anlotinib 8
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 8 mg once daily and Fluzoparib 150 mg twice daily until disease progression or intolerable toxicity
Trial: 37580663
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of enteral cholecalciferol (10,000 IU/kg, maximum of 400,000 IU)
Trial: 37580773
Drug: Ribociclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib plus endocrine therapy (ET) including letrozole, fulvestrant, or tamoxifen with goserelin.
Trial: 37581593
Drug: Mosunetuzumab with
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosunetuzumab with CHOP chemotherapy
Trial: 37581616
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of chemotherapy (PCC)
Trial: 37581673
Drug: Vaginal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estrogen (1 g of conjugated estrogen cream, 0.625 mg/g)
Trial: 37581981
Drug: Midostaurin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin (50 mg twice daily) plus chemotherapy (idarubicin or daunorubicin) for 21 days
Trial: 37581981
Drug: Midostaurin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin (50 mg twice daily) plus chemotherapy
Trial: 37582096
Drug: Fruit and
RxNorm normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit and 100% fruit juice (low doses, up to or less than ~10% E)
Trial: 37582096
Drug: Mixed sources
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed sources (with sugar-sweetened beverages [SSBs]) at high doses (up to 23%)
Trial: 37582170
Drug: Tricuspid transcatheter
RxNorm normalized name: Maclura tricuspidata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricuspid transcatheter edge-to-edge repair with the TriClip implant
Trial: 37582474
Drug: Manual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual physical therapy (3 sessions)
Trial: 37582633
Drug: Recreational drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational drug use (positive test for recreational drugs)
Trial: 37582633
Drug: Multiple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple drug detection (28% of positive patients)